Ann: Avalon Drill Program to Commence, page-97

Sometimes, it's perfectly fine to accept that you missed out on a stock run. Many stocks fluctuate due to hype, anticipation, or assay results. In the biotech sector, for instance, FDA approvals can lead to significant changes: a successful Phase 2 trial might be followed by a failed Phase 3.

The bottom line is, you've been adamant about this stock being overpriced. Sure, there are plenty of overpriced stocks that perform well for a time (like WTC, PME, etc.), but look at where they are now. It's time to stop the overpricing rhetoric and, for once, be happy for the current holders who are making gains.We've heard your complaints since you entered at 3 cents—enough already.

The fact is, you're not a holder, and it seems like you're just trying to create fear and downramp for no good reason. Get a life. Come back and say "I told you so" after the drilling results are in